Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Adenocarcinoma, Follicular 1

Interventions

Magnetic Resonance Spectroscopy 4Specimen Handling 3lutetium Lu 177 dotatate 2Bevacizumab 2regorafenib 1olaparib 1neratinib 1gallium Ga 68 dotatate 1capivasertib 1cabozantinib 1brigatinib 1abemaciclib 1Watchful Waiting 1Tablets 1Surveys and Questionnaires 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Protons 1Proton Therapy 1Observation 1Nivolumab 1Lysine 1Ipilimumab 1Hydroxyurea 1HhAntag691 1Ga(III)-DOTATOC 1GSK2256098 1Everolimus 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × gallium Ga 68 dotatate × 30 days × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡